Treatment of Advanced Hepatocellular Carcinoma by Aryan, Mahmoud et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books







Treatment of Advanced 
Hepatocellular Carcinoma
Mahmoud Aryan, Ellery Altshuler, Xia Qian and Wei Zhang
Abstract
Hepatocellular Carcinoma (HCC) is the fifth most common cancer and  
represents the fourth most common cause of cancer related death worldwide. 
Treatment of HCC is dictated based upon cancer stage, with the most universally 
accepted staging system being the Barcelona Clinic Liver Cancer (BCLC) staging 
system. This system takes into account tumor burden, active liver function, and 
patient performance status. BCLC stage C HCC is deemed advanced disease, which 
is often characterized by preserved liver function (Child-Pugh A or B) with poten-
tial portal invasion, extrahepatic spread, cancer related symptoms, or decreased 
performance status. Sorafenib has been the standard treatment for advanced HCC 
over the past decade; however, its use is limited by low response rates, decreased 
tolerance, and limited survival benefit. Researchers and clinicians have been 
investigating effective treatment modalities for HCC over the past several years 
with a focus on systemic regimens, locoregional therapy, and invasive approaches. 
In this systemic review, we discuss the management of advanced HCC as well as the 
ongoing research on various treatment opportunities for these patients.
Keywords: hepatocellular carcinoma, advanced stage, systemic therapy, locoregional 
therapy
1. Introduction
Primary liver cancer represents an enduring global threat as the fifth most 
common cancer worldwide and the second highest global cause of cancer-related 
mortality [1]. The most common form of liver cancer is hepatocellular carcinoma 
(HCC), which makes up over 90% of primary hepatic malignancies and inde-
pendently represents the fourth most common cause of cancer-related death 
worldwide [2, 3]. Hepatotropic viruses such as hepatitis B virus (HBV), hepatitis C 
virus (HCV), and hepatitis D virus (HDV) are the most common causes of HCC, 
accounting for at least 80% of cases. HCC is also prevalent in individuals with 
underlying cirrhosis with other risk factors being alcohol use, non-alcoholic fatty 
liver disease (NAFLD), diabetes mellitus, obesity, aflatoxin exposure, hereditary 
hemochromatosis, tobacco use, oral contraceptive use, and other inherited meta-
bolic disorders including tyrosinemia and glycogen storage disease type 1  
(Von Gierke disease) [4–7].
The American Association for the Study of Liver Disease (AASLD) recommends 
that adults with cirrhosis undergo screening for HCC given the overall observed 
mortality benefit. Surveillance consists of abdominal ultrasonography every six 
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months either with or without alpha fetoprotein (AFP) measurement. Patients who 
have a lesion ≥ 1 cm or AFP measurement ≥ 20 ng/mL are recommended to undergo 
further diagnostic evaluation with multiphasic computed tomography (CT) scan 
or magnetic resonance imaging (MRI) of the abdomen [8, 9]. In some instances, 
HCC can be diagnosed radiographically via LI-RADS criteria (LR-5 is diagnostic), 
which consists of imaging findings of washout, enhancing capsule, and threshold 
growth in addition to overall size diameter increase over the course of months [10]. 
In instances in which lesions are indeterminate or cannot be diagnosed radiographi-
cally, patients typically undergo either biopsy or close interval repeat imaging [8].
Solid tumor oncological staging is usually based on the tumor (T), node (N), 
and metastasis (M) classification system. This system does not take into account 
the degree of liver dysfunction or patient performance status and is less useful 
for predicting the course of HCC [9]. The Barcelona Clinic Liver Cancer (BCLC) 
staging system is the most universally accepted staging system for HCC as it takes 
into account tumor burden, liver functional status, and patient performance 
status. In the BCLC system, patients are classified into different stages, including 
very early (BCLC stage 0), early (BCLC stage A), intermediate (BCLC stage B), 
advanced (BCLC stage C), and terminal (BCLC stage D). Very early to early-stage 
HCC (BCLC stage 0 or A) cancers are treated with curative intent through resec-
tion, ablation, or even liver transplant (LT); overall survival is as high as 75% at 
5 years. The standard of care for patients with intermediate stage HCC (BCLC 
stage B) is transarterial chemoembolization (TACE) or transarterial radioembo-
lization (TARE). Patients with advanced HCC (BCLC stage C) often present with 
cancer-related symptoms but usually have moderately preserved liver function 
(Child-Pugh A or B). These patients receive systemic therapy, though other treat-
ment modalities are under investigation. BCLC stage D HCC is considered terminal 
and is usually managed with best supportive care [11, 12].
Unfortunately, over 80% of HCC are diagnosed at the advanced stage (BCLC 
stage C or D). Therapy options such as TACE and tumor resection are often 
not appropriate in these patients, and 5-year survival is as low as 18% [13, 14]. 
Researchers and physicians have been investigating potential effective treatment 
options in these patients in the past decade and have made great advances. In this 
systemic review, we summarize the latest strategies and upcoming methods of 
managing advanced (BCLC stage C) HCC.
2. First line systemic therapy
HCC has been historically considered a chemotherapy-resistant tumor. Most 
chemotherapy agents require hepatic metabolism and cannot be used in the set-
ting of severely impaired liver function [15]. Overall survival is often dictated by 
underlying hepatic function rather than extensive tumor burden. Despite these 
challenges, researchers have applied targeted immunotherapy for advanced HCC 
treatment and, at least in certain clinical scenarios, have found benefit [16].
2.1 Atezolizumab + Bevacizumab combination therapy
Multi-agent combination therapy with atezolizumab and bevacizumab has 
recently replaced sorafenib as first line treatment for advanced HCC. Atezolizumab 
and bevacizumab are monoclonal antibodies that target program death ligand 1 
(PD-L1) and vascular endothelial growth factor (VEGF), respectively [17, 18]. 
When used together, these medications inhibit both T cell apoptosis and angiogen-
esis. The combination of these medications was compared to sorafenib in patients 
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with treatment naïve advanced HCC in the IMbrave150 trial. The trial showed that 
patients treated with atezolizumab and bevacizumab had significantly improved 
overall survival (OS) and progression free survival (PFS) when compared to those 
treated with sorafenib [17]. Adverse events occurred at similar rates among the two 
groups, with the most common adverse effects in patients given atezolizumab with 
bevacizumab being hypertension and proteinuria. Following systemic review of 
nine randomized control trials, the American Society of Clinical Oncology (ASCO) 
has deemed combined atezolizumab/bevacizumab as the first line treatment 
for advanced HCC applicable to those with Child-Pugh A liver disease, Eastern 
Cooperative Oncology Group Performance Status (ECOG PS) no higher than one 
and treated esophageal varices (EV) [18]. Recent updates from Finn and colleagues 
on the IMbrave150 trial reported that median OS was 19.2 months in those taking 
atezolizumab and bevacizumab vs. 13.4 months in those taking sorafenib (HR, 0.66 
[95% CI, 0.52, 0.85]; P=0.0009). At 18 months, those treated with atezolizumab 
and bevacizumab had an OS of 52% while patients on sorafenib has an OS of 40%. 
Atezolizumab and bevacizumab combination therapy has demonstrated the longest 
OS in a front-line phase III clinical study for advanced HCC to date and remains the 
standard of care for treatment-naïve, advanced HCC [19].
2.2 Sorafenib
Tyrosine protein kinase inhibitors (TKIs) had been at the forefront of advanced 
HCC treatment for quite some time. The first TKI approved by the Food and Drug 
Administration (FDA) for treatment of advanced HCC was sorafenib, which was 
first approved for treatment of unresectable HCC in 2007 (Table 1). This TKI tar-
gets VEGF, platelet derived growth factor (PDGF), and others molecular pathways 
to inhibit angiogenesis [20]. The Sorafenib Hepatocellular Carcinoma Assessment 
Randomized Protocol (SHARP) study was the first multi-center, placebo-con-
trolled, phase III clinical trial in untreated, Child-Pugh A advanced HCC patients, 
and demonstrated a 2.8-month overall survival (OS) in those treated with sorafenib 
versus placebo (10.7 vs. 2.9 months) [21]. Further clinical trials and subset analysis 
showed that sorafenib provides survival benefit in patients with HCC not amend-
able to loco-regional therapy, though the benefit appears to be greater for patients 
Regimen ASCO recommendations Criteria for use
Atezolizumab + 
Bevacizumab
First-line ECOG PS ≤ 1, Child-Pugh A, following EV 
treatment
Sorafenib First-line When there are contraindications to 
Atezolizumab – Bevacizumab therapy
Lenvatinib First-line
Nivolumab First-line or Second-line
Cabozantinib Second-line or Third-line
Regorafenib Second-line Those who failed Sorafenib






American Society of Clinical Oncology (ASCO) recommendations for systemic therapy in advanced (BCLC 
stage C) HCC [18].
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with Child Pugh A cirrhosis than Child Pugh B cirrhosis [22]. Cheng et al. per-
formed a randomized, double-blind, placebo control trial of sorafenib in the Asian 
Pacific region in patients with advanced HCC. Following six weeks of therapy, 
patients treated with sorafenib had significantly higher median OS (6.5 months 
vs. 4.2 months; [HR] 0.68 [95% CI 0.50–0.93]; p=0.014) and time to progression 
(2.8 months vs. 1.4 months; HR 0.57 [0.42–0.79]; p=0.0005) [23]. Despite the 
clinical benefits of sorafenib, many patients are unable to tolerate the significant 
side-effects, which include diarrhea, hand and feet skin irritation, weight-loss, and 
electrolyte derangements [21, 24, 25]. With its OS benefits and effects on disease 
progression, sorafenib remains a first-line option for advanced HCC [18].
2.3 Lenvatinib
Following the success of Sorafenib, several other TKIs were developed as 
potential treatment options in advanced HCC patients. Lenvatinib is a TKI that 
targets multiple pathways within angiogenesis including VEGF receptors, fibro-
blast growth factor (FGF) receptors, platelet derived growth factor (PDGF) alpha 
as well as RET and KIT [26]. An open-label, multicenter, phase III clinical trial 
known as the REFLECT trial showed lenvatinib to be non-inferior to sorafenib in 
advanced HCC patients with respect to OS. In the same trial, patients treated with 
lenvatinib had a higher incidence of hypertension, decreased appetite, and weight 
loss, while those treated with sorafenib had a higher incidence of hand-foot skin 
reaction (HFSR) and diarrhea. Patients treated with lenvatinib had significantly 
better progression-free survival (PFS) (7.4 months vs. 3.7 months, p < 0.001), time 
to progression (8.9 months vs. 3.7 months, p < 0.001), and objective response rate 
(24.1% vs. 9.2%, p < 0.001) [25, 27]. Vogel et al. analyzed prognostic factors of the 
REFLECT trial and reported that baseline liver function tests such as albumin-
bilirubin grade and Child-Pugh score were predictive of OS. These markers may be 
used to monitor overall safety and efficacy of lenvatinib treatment. Regardless of 
baseline liver function, lenvatinib led to longer OS than sorafenib [28]. Given this 
data, the ASCO now considers lenvatinib a reasonable first-line treatment option 
for advanced HCC [18].
Ongoing studies are being conducted on the use of lenvatinib alongside 
nivolumab, an anti-PD-1 monoclonal antibody often used as second line therapy for 
HCC, in patients with unresectable, advanced HCC. Early results from the phase 
1b trial of this open label study show that lenvatinib combined with nivolumab is 
well tolerated in BCLC stage C HCC with multiple patients demonstrating partial or 
complete response [29].
3. Second line systemic therapy
3.1 Cabozantinib
Other agents have been investigated for advanced HCC for patients with disease 
resistant to first-line therapy. Cabozantinib is a TKI that targets mesenchymal-
epithelial transition (MET) factor to disrupt hepatocyte growth factor pathway, a 
pathway that is often important for HCC oncogenesis [30]. A phase III clinical study 
known as the CELESTIAL trial showed that for patients who had suffered disease 
progression while on sorafenib, cabozantinib led to longer OS and PFS than placebo 
[31–33]. Although adverse effects such as diarrhea, HFSR, hypertension, nausea, 
and decreased appetite, were found to be twice as high in the cabozantinib group 
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than in the placebo group, the effects were generally mild and considered manage-
able [31–33]. Given its clinical benefit, the ASCO has classified cabozantinib as a 
second-line therapy for advanced HCC [18].
3.2 Regorafenib
Regorafenib is another TKI that has been utilized as a second-line agent in 
advanced HCC [18, 34, 35]. The RESORCE trial along with other studies support 
the use of regorafenib in treatment-resistant advanced HCC with active investiga-
tions focusing on applying the use of regorafenib in combination with other medi-
cations against advanced HCC [36]. When comparing cabozantinib and regorafenib 
as second line therapy in patients who had failed sorafenib therapy, the side effect 
profile of these medications was similar (with only increased incidence of diarrhea 
in patients taking Regorafenib), and both therapies provided similar benefits in 
regard to OS and PFS [37].
3.3 Apatinib
The latest TKI to show efficacy in advanced HCC is a VEGF receptor inhibitor 
called apatinib. This medication had been implemented in patients with hepatitis B 
infection in the past. Li et al. performed a multi-center, double blind, randomized 
phase III control trial in China in patients with advanced HCC refractory to at least 
one systemic agent [38]. The median OS was significantly higher in those treated 
with apatinib compared to placebo (8.7 months vs. 6.8 months, p < 0.05). The most 
common adverse effects of apatinib were hypertension, thrombocytopenia, and 
HFSR [38].
3.4 Nivolumab
Clinicians have also applied the use immunomodulatory checkpoint inhibitors as 
treatment for advanced HCC. Nivolumab is an immunoglobulin (IgG) 4 antibody 
that targets program death 1 (PD-1) on the surface of T cells to promote the anti-
tumor properties of T cells [39]. Clinical trials have shown nivolumab to be a safe 
treatment option for advanced HCC with non-comparison studies showing durable 
and effective clinical response to treatment [40]. Multicenter phase III clinical trials 
comparing nivolumab to sorafenib are currently underway [41, 42]. Interim results 
of the CheckMate 459 trial, a randomized, multicenter phase III study, have shown 
no significant difference in median OS between nivolumab and sorafenib; however, 
the objective response rate was as high as 15% in those taking nivolumab vs. 7% 
in those taking sorafenib [41, 42]. Additionally, nivolumab was associated with 
superior health-related quality of life with patients reporting fewer side effects [43].
3.5 Pembrolizumab
Pembrolizumab is another monoclonal antibody directed against PD-1 that has 
been used as therapy for patients with advanced HCC [44]. The KEYNOTE trials 
were conducted to evaluate the efficacy of pembrolizumab and were expanded 
to compare the use of pembrolizumab following disease progression while on 
sorafenib to best supportive care. Despite pembrolizumab reducing the risk of 
death by 22%, there was no significant difference in OS between the two groups 
[44, 45]. Continued research is ongoing regarding the use of this anti-PD-1 agent 
for advanced HCC treatment.
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3.6 Ramucirumab
Ramucirumab is a monoclonal antibody directed against vascular endothelial 
growth factor receptor 2 (VEGFR-2) that is approved for advanced HCC therapy 
in patients with alpha-fetoprotein (AFP) levels ≥400 ng/mL. Ramucirumab 
was initially compared versus placebo in a double-blind, multicenter, random-
ized control phase III trial known as REACH-1; unfortunately, there was no 
statistically significant difference in OS for those given ramucirumab or placebo 
in those who had failed first line sorafenib therapy [46]. Following subgroup 
analysis of the REACH-1 trial, the REACH-2 trial showed that ramucirumab had 
a statistically significant survival benefit compared to placebo in patients with 
AFP ≥400 ng/mL [47, 48]. The side-effect profile of ramucirumab is mild, with 
only reported increased frequency of hypertension and proteinuria, making 
it a second-line therapy for advanced HCC by the ASCO for patients with AFP 
≥400 ng/mL [18, 46, 47]. Given its specific target population, ramucirumab is not 
routinely used in HCC patients with AFP <400 ng/mL.
3.7 Ipilimumab
Ipilimumab is a monoclonal antibody that targets cytotoxic T-lymphocyte-
associated protein 4 (CTLA-4) to downregulate immune function. The Checkmate 
040 trial assessed the use of ipilimumab alongside nivolumab for advanced HCC 
patients and demonstrated combination therapy to have an object response rate 
twice as high as nivolumab monotherapy (31% vs. 14%) This combination therapy 
was also well tolerated with an acceptable side effect profile when compared to 
similar systemic therapy [49, 50].
The Checkmate 040 trial was expanded to investigate triple combination 
therapy consisting of nivolumab, ipilimumab, and cabozantinib altogether [51]. 
When compared to the combination of just nivolumab and ipilimumab, those on 
triple therapy had a longer period of progression-free survival (6.8 months vs. 
5.5 months). Treatment related adverse events were higher in those taking triple 
therapy with a discontinuation rate of 20% in the triple therapy group and 3% in 
the double therapy group [51].
4. Locoregional therapy
Therapies in the form of embolization fall under the category of locoregional 
therapy and are typically contraindicated in patients with advanced HCC with 
underlying vascular invasion, extrahepatic spread, or poor performance status. 
However, some patients with advanced HCC classified as BCLC stage C have 
benefited from locoregional therapies [52].
4.1 TACE
Advanced HCC patients with tumor invasion off a branch of the portal vein or 
limited extrahepatic disease involvement have been trialed with TACE therapy [53]. 
TACE consists of injecting an emulsified chemotherapeutic agent into the hepatic 
artery flowing towards the underlying tumor, followed by embolization of the ves-
sel to contain the drug and localize cell death within the malignancy [52, 53]. TACE 
has historically been more successful in localized disease without extrahepatic or 
diffuse vascular involvement and serves as the first-line treatment for intermedi-
ate (BCLC stage B) HCC. Consensus regarding the overall clinical utility of TACE 
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in advanced HCC when compared to systemic therapy remains under discussion 
[54]. Certain studies have shown TACE to be clinically safe and feasible in select 
advanced HCC patients with good collateral blood flow, and a meta-analysis 
reported TACE to be associated with higher treatment responses in advanced HCC 
when compared to other more conservative treatment approaches [54]. However, a 
retrospective analysis by Pinter and colleagues demonstrated no significant differ-
ence in OS between patients treated with TACE versus sorafenib, with Child-Pugh 
class predicting OS in these patients [55]. Meanwhile, Choi et al., reported through 
retrospective analysis that TACE in addition to sorafenib is associated with signifi-
cantly increased time to progression when compared to sorafenib therapy alone, 
though no difference was seen with regard to OS [56]. Other retrospective studies 
including the TACTICS trial also found that combining TACE with sorafenib in 
advanced HCC improved progression-free survival when compared to sorafenib 
therapy alone [57–61].
4.2 Y-90 trans-arterial radio-embolization
Y-90 trans-arterial radio-embolization (TARE) is a therapy modality by which 
the isotope yttrium90 is delivered in in small vector beads to malignancy areas 
through branches of the hepatic artery [62]. TARE has been applied to treat-
ment of advanced HCC in tumors that invade discrete segmental areas of the 
liver. Additionally, TARE has been shown to decrease overall portal vein tumor 
thrombus load [62]. Recent data indicates that when comparing the efficacy of 
TARE vs. sorafenib in advanced HCC patients, those who underwent TARE had a 
significantly higher tumor response rate, though there was no significant difference 
in OS [63]. Studies have also been conducted on combining TARE with systemic 
therapy in advanced HCC. No clear benefit was seen when combining TARE with 
sorafenib [64]; however, there have been case reports or series of positive outcomes 
in combining TARE with different systemic modalities [65, 66].
Most recently, a multicenter, single-arm, retrospective study conducted at three 
separate medical centers called the LEGACY study assessed the clinical efficacy of 
TARE therapy in unrespectable HCC [67]. Chemoembolization served as a primary 
treatment for 72.2% of the cohort with advanced disease. The three-year OS rate 
for the entire cohort was 86.6% with 62.2% of patients experiencing a duration of 
response of greater than six months [67]. This study led to the FDA approval of 
TheraSphere Y-90 Glass Microsphere for treatment of advanced HCC [68].
Garin et al. conducted research on the dosimetry of TARE therapy through a 
randomized, multicenter, open-label phase II trial known as DOSISPHERE-01 [69]. 
Patients received either a standard dose of Y-90 to the perfused lobe or a personal-
ized dose of Y-90 targeted to the index lesion. Results showed that personalized 
dosimetry significantly improved response rates when compared to standard 
dosimetry in cases of locally advanced HCC (71% vs. 35%, p < 0.01) [69].
4.3 Hepatic artery infusion chemotherapy
Hepatic artery infusion chemotherapy (HAIC) has been used in the treatment 
of advanced HCC to directly delivery high concentrations of chemotherapeutic 
agents [70]. Studies on advanced HCC lesions that were unresectable, refractory to 
TACE, or associated with portal vein thrombus (PVT) have demonstrated posi-
tive responses to HAIC within patient cohorts. Groups in Korea and Japan have 
implemented HAIC with agents including cisplatin, 5-fluororuacil (5-FU), and 
pegylated interferon α-2b [70]. A randomized trial comparing interferon therapy 
coupled with 5-FU HAIC to sole interferon therapy in advanced HCC patients 
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showed a significantly higher response rate (45.6% vs. 24.6%, p < 0.05) and longer 
median progression free survival (6.5 months vs. 3.3 months, p=0.0048) in the 
patients who received HAIC [71]. In their study comparing HAIC and sorafenib 
in advanced HCC patients, Song and colleagues reported that the median overall 
survival was significantly longer in the patients who received HAIC (OS: 7.1 months 
vs. 5.5 months, p < 0.05) [72].
5. Surgery
As medical and surgical expertise continue to improve, surgery is no longer 
contraindicated in some advanced HCC patients [73]. Surgical resection of 
advanced HCC, either in the form of hepatectomy or en-bloc resection, has been 
revisited as a potentially efficacious way of increasing OS. Data has shown that the 
overall median survival time in advanced HCC patients with PVT who undergo 
surgical resection to be between 8 and 22 months, with OS between 21.7% to 
69.6% at one year [74]. Given the high incidence of post-operative recurrence, 
multi-disciplinary approach to surgical planning on a case-by-case basis is needed 
[74, 75]. Liang and colleagues performed a meta-analysis and found that patients 
who underwent surgical resection of advanced HCC with PVT had longer OS than 
those who were treated with TACE therapy [76].
The combination of systemic therapy with surgical resection has also been 
applied to advanced HCC patients. Takeyama et al. studied the use of sorafenib as a 
potential neo-adjuvant therapy prior to surgical resection. Patients who underwent 
surgical resection following treatment with sorafenib had a significantly increased 
three-year survival than patients who underwent therapy with sorafenib alone [77]. 
Incorporating surgical resection with other treatment modalities including TACE 
and radiofrequency ablation have also promoted positive prognostic outcomes in 
select patients [74, 75]. Overall, the indication for surgical therapy in advanced 
HCC patients with or without PVT requires a multi-disciplinary approach and may 
entail utilizing systemic or locoregional therapy during treatment planning.
6. Future directions
Several systemic agents have been trialed for treatment of advanced HCC over 
the past decade. As newer agents are approved for use in advanced HCC, combined 
treatment options remain intriguing topics for investigation. Gosain et al. have 
hypothesized that sorafenib and pembrolizumab may have synergistic effects and 
are currently conducting a trial to evaluate the efficacy of these drugs when used in 
combination [78]. Given the favorable response rates of nivolumab that were seen in 
the Checkmate 040 trial, Welling et al. are conducting a phase II, randomized con-
trol of nivolumab combined with HuMax-IL8 and cabiralizumab (an anti-CSF1R 
antibody) in advanced HCC patients. HuMax-IL8 (now known as BMS-986253) is 
a novel, fully human monoclonal antibody that inhibits interleukin-8 (IL-8) [79]. 
Combining locoregional with systemic therapy is also under investigation [80]. 
Among multiple studies being conducted, the EMERALD-1 trial is a randomized, 
double-blind, placebo-controlled phase III study assessing anti-PD-1 agent dur-
valumab alongside TACE therapy with or without bevacizumab [81].
Alternative molecular targets are also being evaluated. El-Khouiery et al. are 
currently working on an advanced HCC phase I trial of humanized agonist IgG2 
monoclonal antibodies to a specific tumor necrosis factor receptor known as OX40. 
Underlying safety and pharmacodynamic dose-dependent response are now being 
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investigated [82]. Another phase I trial currently underway involves a small activat-
ing RNA (saRNA) known as MTL-CEBPA that targets transcription factor C/EBP-α, 
which is involved in hepatic homeostasis and cell-cycle control. The preliminary 
results showed that it is relatively safety and can have potential synergistic efficacy 
with tyrosine kinase inhibitors in HCC [83]. Like new combinations of locore-
gional-systemic combinations and new uses of systemic agents, novel molecular-
targeting agents offer hope for improved outcomes in advanced HCC.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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